pexacerfont
Small moleculeexperimental
Pexacerfont (INN, previously known as BMS-562,086) is a drug developed by Bristol-Myers Squibb which acts as a CRF1 antagonist. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00135421)
Timeline
Indications
Mechanism of action
CRHR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@H](C)Nc1nc(C)nc2c(-c3ccc(OC)nc3C)c(C)nn12- Mol. weight
- 340.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPexacerfont ↗
- ChEMBLCHEMBL482950 ↗
Also known as
- bms-562086
- bms-562086
- bms-562086
- bms-562086
- crf1 antagonist
- crf1 antagonist
- pexacerfont
- pexacerfont
- pexacerfont
- pexacerfont
- pexacerfont
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01656577 | Early Phase 1 (Phase 1) | Jun 1, 2012 | National Institute on Drug Abuse (NIDA) |
| NCT01227980 | Phase 2 | Oct 1, 2010 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT00481325 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2007 | Bristol-Myers Squibb |
| NCT00399438 | Phase 2 | Dec 1, 2006 | Bristol-Myers Squibb |
| NCT00135421 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2005 | Bristol-Myers Squibb |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 3 | 2 | 2005 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 1 | 1 | 2010 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 1 | 1 | 2012 |
3 organizations
Page 1 / 1